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Care on prevention and treatment of rare (orphan) diseases’ has been recently 
issued. It governs the measures of OD prophylaxis. Methods: According to the 
Law, in order to improve OD patient care, a work on medical and technological docu-
ments on such topics as mucopolysaccharidosis, Gaucher disease, phenylketonuria, 
hemophilia was launched. The development of medico-technological documents 
was done in a few steps. Firstly, the search for clinical guidelines was conducted 
in the GIN library and other sources. Secondly, the primary selection and appraisal 
with AGREE II instrument have been carried out. The next step was adaptation of 
clinical guidelines and development of clinical protocols of the medical care. It 
was conducted by multidisciplinary working groups including leading specialists 
in clinical genetics, health care managers and patients organizations. Results: 
Today the clinical protocols of treatment of mucopolysaccharidosis patients, based 
on evidence of the effectiveness of medical technologies, pharmacotherapy and 
organizational principles of its provision, were approved. The documents contained 
modern approaches for diagnostics and treatment of mucopolysaccharidosis, which 
are ajusted to the health care system of Ukraine. ConClusions: Harmonization 
of treatment practices of OD in Ukraine with international best practice will bring 
the treatment of these states in Ukraine to a new level and provide thorough meas-
ures aimed at the development of screening and prevention programs, diagnostics 
and treatment, as well network collaboration among health services, educational 
institutions, public etc.
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objeCtives: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder 
that can cause multi-organ damage, leading to reduced life expectancy, lower qual-
ity of life, and high medical expenditures. Therefore, long-term and comprehensive 
disease management and monitoring are important. This study aimed to examine 
treatment pattern, quality of SLE care, and utilization and costs of medical care of 
SLE patients. Methods: The National Health Insurance Research Database was 
adopted to identify patients diagnosed with SLE before 2010 through their eligibility 
for catastrophic illness of SLE, and examine their use and costs of health services 
in 2010. Logistic regression models and generalized linear models were adopted 
for analyses. Results: The majority of 744 patients with SLE was female (85%), 
older than 40 years old (54%), and having been diagnosed with SLE for more than 
five years (68%). Sixty-one percent of them received corticosteroids, 59% received 
antimalarials, and 36% received immunosupressants. Annual tests for complete 
blood count, creatinine, and serum levels of complement component C3/C4 and 
anti-dsDNA antibodies were received by 85%, 78%, and 76% of the subjects, respec-
tively. Forty-four percent of them received annual evaluation of cardiovascular risk, 
and 3% of them received influenza vaccination. Average number of outpatient visit 
was 33.47, and SLL-related visit was 12.82. Twenty-two percent of them were admit-
ted to hospital during the year, and the average number of hospital admission was 
0.48. The average annual medical cost was NTD105,059, and the average SLE-related 
medical cost was NTD29,770. Shorter time since SLE diagnosis was associated with 
more intense treatment, better adherence to recommendations for annual tests, and 
higher SLE-related costs. ConClusions: This study identified treatment pattern, 
quality of SLE care, and use and costs of patients with SLE. Disease management 
and monitoring need to be improved.
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objeCtives: To investigate the global perspectives of Turkish Rheumatologists 
regarding expected FMF prevalence, undiagnosed patients ratio, arguments in diag-
nostic procedure and management of FMF. Methods: A questionnaire consist of 
estimated frequency, diagnostic modalities and follow up characteristics in addition 
to therapeutic approach was set up. Even though a regular colchicine use, ≥ 1 attack /
month during 6 months was accepted as colchicine resistant. All members of Turkey 
Society for Rheumatology from country wide (n= 235) were invited to fill in the 
web-based questionnaire for FMF by e-mail. Totally 108 members (45.9%) answered 
the questionnaire. Results: Estimated prevalence was median 0.2% (IQR25-75: 
0.1-0.7) for FMF. Only 51.4±19.0 % of these patients had been diagnosed according 
to Rheumatologists opinion. Time to diagnosis from the first symptom was more 
than 3 years in 49.5% of patients. Description of typical attacks in anamnesis is the 
most frequent parameter in diagnosis of patients whereas in 26.7 %of patients MEFV 
mutations were required for diagnosis. 53.5 ±21.3 % of patients were on regular 
follow up and 75.7% of these follow up was with a 3-6 months period. Frequency 
of Colchicine resistant patients was expected in 7.2%. The use of biologic agents in 
the patients followed up by these physicians was expected as 3.4%. ConClusions: 
Since half of the estimated prevalence was expected as undiagnosed and patients 
have a 3-years delay in diagnosis, Medical and Social Activities are required to 
increase the awareness of FMF. Less than 5 percent of patients required biologic 
agents in FMF.
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observed for age, pharmacologic treatment and disease severity. No significant 
statistical effect was observed for gender, late onset patients (> 50 years) and liver 
transplant. ConClusions: The preference-based utility measures used in this 
study adequately disentangle TTR-FAP impact on patient’s quality of life and allow 
discriminating across different TTR-FAP clinical severity states, interventions and 
demographic characteristics. Assuming that these values represent the patients’ 
preferences and the utility associated with their health state, the results presented 
in this study may be used in future health technologies cost-utility studies.
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objeCtives: Immune thrombocytopenia (ITP) is associated with a risk of spontane-
ous and excessive bleeding. Among the treatment options are medical therapies and 
splenectomy – a major intervention with lifelong consequences for the patient. Both 
ITP and ITP-treatment may impact health-related quality of life (HrQoL); therefore, 
a literature search was conducted to assess HrQoL of splenectomized compared to 
non-splenectomized ITP patients. Methods: A targeted literature search was con-
ducted via Ovid (Medline, Embase, and Cochrane) in September 2014. Search strings 
were based on PICO-criteria (Patient, Intervention, Comparison and Outcomes). 
Inclusion criteria were: studies of adult patients with ITP that contained information 
on HrQoL; clinical trials, RCTs, meta-analyses, observational trials, retrospective 
studies or systematic reviews; manuscripts and congress abstracts in English or 
German language. Results: The search identified 148 potentially relevant publica-
tions. After removing duplicates, 120 titles and abstracts were screened. Following 
the title/abstract screening, a full text screening (n= 21) identified six relevant pub-
lications. HrQoL was assessed in these six publications using generic (SF-36, n= 2; 
EQ-5D, n= 1) and disease-specifc (ITP-PAQ, n= 4) instruments. Two studies using 
generic instruments reported no difference in HrQoL between splenectomized and 
non-splenectomized patients. Of the four studies using the ITP-PAQ, two reported 
no difference and two found worse HrQoL in splenectomized versus non-splenec-
tomized patients. In the only study that included both generic (SF-36, EQ-5D) and 
ITP-specific measures, results were inconsistent, as they varied in outcomes. Overall 
detailed results were not always provided and HrQoL was not reported according 
to response to therapy in any study. ConClusions: The impact of splenectomy 
on HrQoL in patients with ITP is inconclusive and inconsistently reported in the 
literature, due to use of different instruments, diverse patient characteristics, and 
pooling of data among responding and non-responding patients. Further studies are 
needed to address this question within clearly-defined populations.
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objeCtives: Treatment for children with GHD involves daily injections which 
may begin at a very early age and continue throughout childhood. However, the 
treatment burden (TB) for children and their parents has not been examined. The 
purpose of this study was to support the content validity of a new GHD-specific TB 
measure, with versions for patient-reported outcome (PRO) for older children, and 
observer-reported outcome (ObsRO) and PRO for parents/guardians. Methods: 
Focus groups and interviews were conducted with 39 children (aged 8–12) with 
GHD, 31 parents of children (aged 4–12) and eight clinical experts in three countries 
(Germany, UK, US). Interviews were analysed and coded using adapted grounded 
theory. A conceptual model of TB was developed and items were generated and 
then cognitively debriefed. Results: Qualitative analysis found saturation was 
reached with three domains for child TB and two domains for parent TB. Child 
domains (and major proximal subdomains) were: Physical (pain, 33% and bruis-
ing, 19%), Interference (Interference with overnight or other activities, 29% and 
Time needed emotionally to prepare for treatment, 23%) and Emotional (Worry, 
about injections, 37%, Unhappiness with injection frequency, 25%, and Fear, 22%). 
Parent TB domains were Emotional (Worry or anxiety about treatment or treat-
ment administration, 58% and Worry about causing pain, 42%) and Interference 
(Time spent preparing and administering injection, 42%, Interference with travel/
vacation, 42%, and Interference with daily/family routines, 35%). The items were 
cognitively debriefed in a new sample (N= 26: 13 children, 13 parents) and, based on 
findings, it was determined that the PRO version was appropriate for children aged 
9–12. The final measure includes 17 items (child PRO and parent ObsRO versions) 
with a 12-item parent PRO module. ConClusions: The conceptual validity of the 
TB-CGHD is supported by these qualitative findings and the measure is now ready 
for psychometric validation.
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objeCtives: There is no integrated approach to the problem of orphan diseases 
(OD) in Ukraine. Diagnosis of these illnesses is often complicated and delayed, the 
treatment is often ineffective because of the lack and unavailability of essential 
medicines and methods of treatment, the quality of life for most patients remains 
poor. The Law of Ukraine ‘On amendments to the Basic Laws of Ukraine on Health 
